What is Moxonidin used for?

Moxonidin is indicated for Essential hypertension.

What development phase is Moxonidin in?

Moxonidin is FDA-approved (marketed).

What is the generic name of Moxonidin?

MOXONIDINE is the generic (nonproprietary) name of Moxonidin.

Last reviewed 2026-04-20 · How we verify

Moxonidin (MOXONIDINE)

FDA-approved approved Small molecule Quality 30/100

At a glance

Generic name	MOXONIDINE
Drug class	moxonidine
Target	Nischarin
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved
First approval	1991

Approved indications

Essential hypertension

Common side effects

No common side effects on file.

Key clinical trials

Autonomic Determinants of POTS - Pilot1 (EARLY_PHASE1)
Autonomic Determinants of POTS - Pilot 2 (EARLY_PHASE1)
Sympathetic Mechanisms in Obesity-Crossover Design (PHASE1,PHASE2)
Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity (PHASE1)
Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease (PHASE4)
Role of Sympathetic Activation in Ischemia Reperfusion Injury (PHASE4)
Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension (PHASE4)
Moxonidine Effects on Neuropeptide Y (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Moxonidin CI brief — competitive landscape report
Moxonidin updates RSS · CI watch RSS